United Laboratories International Holdings (United Laboratories International Holdings) Debt-to-Equity : 0.12 (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is United Laboratories International Holdings Debt-to-Equity?

United Laboratories International Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $28 Mil. United Laboratories International Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $183 Mil. United Laboratories International Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,784 Mil. United Laboratories International Holdings's debt to equity for the quarter that ended in Dec. 2023 was 0.12.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for United Laboratories International Holdings's Debt-to-Equity or its related term are showing as below:

ULIHF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.12 Med: 0.72 Max: 1.06
Current: 0.12

During the past 13 years, the highest Debt-to-Equity Ratio of United Laboratories International Holdings was 1.06. The lowest was 0.12. And the median was 0.72.

ULIHF's Debt-to-Equity is ranked better than
68.98% of 851 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs ULIHF: 0.12

United Laboratories International Holdings Debt-to-Equity Historical Data

The historical data trend for United Laboratories International Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Laboratories International Holdings Debt-to-Equity Chart

United Laboratories International Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.75

0.26

0.20

0.23

0.12

United Laboratories International Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.20	0.22	0.23	0.13	0.12

Competitive Comparison of United Laboratories International Holdings's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

United Laboratories International Holdings's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Laboratories International Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where United Laboratories International Holdings's Debt-to-Equity falls into.

United Laboratories International Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

United Laboratories International Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(28.061	+	182.533)	/	1783.532
	=	0.12

United Laboratories International Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(28.061	+	182.533)	/	1783.532
	=	0.12

United Laboratories International Holdings (OTCPK:ULIHF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

United Laboratories International Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of United Laboratories International Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

United Laboratories International Holdings (United Laboratories International Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » United Laboratories International Holdings Ltd (OTCPK:ULIHF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

03933:Hong Kong UNJ:Germany

Address

No. 6 Fuk Wang Street, Yuen Long Industrial Estate, New Territories, Hong Kong, HKG

Website

http://www.tul.com.cn

United Laboratories International Holdings Ltd is a major drug manufacturing company. United Laboratories is organized into three revenue streams, including Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. Most of the company's sales are generated in China, followed by Europe and India.

United Laboratories International Holdings (United Laboratories International Holdings) Headlines

No Headlines